Rising cancer antigen 125 level and the type and timing of treatment for recurrent ovarian cancer: a clinical dilemma, but what would women do?

Harrison, James D; Juraskova, Ilona; Anderson, Caroline; Nattress, Kathryn; Beale, Philip; Lopez, Anna-Lena; Carter, Jonathan

Harrison, James D; Juraskova, Ilona; Anderson, Caroline; Nattress, Kathryn; Beale, Philip; Lopez, Anna-Lena; Carter, Jonathan.

Affiliation

Harrison JD; Surgical Outcomes Research Centre, Sydney South West Area Health Service and School of Public Health, University of Sydney, New South Wales, Australia. james.harrison@email.cs.nsw.gov.au

Int J Gynecol Cancer ; 19(6): 1037-46, 2009 Aug.

Article in En | MEDLINE | ID: mdl-19820365

Subject(s)

CA-125 Antigen/blood; Decision Making; Neoplasms, Glandular and Epithelial/psychology; Neoplasms, Glandular and Epithelial/therapy; Ovarian Neoplasms/psychology; Ovarian Neoplasms/therapy; Patient Preference; Antineoplastic Protocols; Biomarkers, Tumor/blood; Female; Humans; Neoplasms, Glandular and Epithelial/blood; Neoplasms, Glandular and Epithelial/diagnosis; Ovarian Neoplasms/blood; Ovarian Neoplasms/diagnosis; Patient Education as Topic; Patient Preference/psychology; Recurrence; Sentinel Surveillance; Social Class; Surveys and Questionnaires; Time Factors; Up-Regulation

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Ovarian Neoplasms / Neoplasms, Glandular and Epithelial / CA-125 Antigen / Decision Making / Patient Preference Type of study: Diagnostic_studies / Prognostic_studies / Qualitative_research Limits: Female / Humans Language: En Year: 2009 Type: Article

Fulltext

XML

PubMed Links

Search on Google